



April 8, 2016

To: Directors of Clinical Laboratories  
Directors of Transfusion Services

Subject: Pathogen Reduced Platelets

LifeSouth is pleased to introduce **INTERCEPT® Platelets** (psoralen-treated; pathogen-reduced apheresis platelets).

INTERCEPT Platelets are *pathogen reduced* components in which a broad spectrum of clinically relevant pathogens and leukocytes have been inactivated, thus reducing the risk of transfusion-transmitted infections and transfusion-associated graft versus host disease.

This product provides a safe alternative to irradiated/CMV products and addresses residual risks related to sepsis, established pathogens such as HIV, HBV, HCV, and emerging pathogens for which tests do not exist, such as Chikungunya, Denge and Zika viruses.

The FDA has approved this technology to replace bacterial detection testing.

***As a ZIKV mitigation strategy, LifeSouth will implement pathogen reduced platelets in Florida, initially. If locally acquired cases of ZIKV are detected, this technology will allow us to continue collections in areas of active transmission in the event a test for ZIKV is not yet available to us for donor screening.***

### New product codes

The following table includes the ISBT component codes currently assigned to pathogen reduced platelets. Your computer system should be able to accept all of these new products *although not all may be in production initially*:

Pathogen Reduced Platelets		Expiry Date
E8331V00	Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Psoralen-treated	5 days
E8332V00	Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 1 <sup>st</sup> container Psoralen-treated	5 days
E8333V00	Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 2 <sup>nd</sup> container Psoralen-treated	5 days
E8334V00	Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 3 <sup>rd</sup> container Psoralen-treated	5 days
E8335V00	Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 <3E11 plts Psoralen-treated	5 days

**Pathogen Reduced Platelets will be available as soon as April 22, 2016.** Conventional platelets will continue to be available as our primary apheresis inventory product.

A representative of LifeSouth will be available to answer any questions you may have. Please feel free to contact Jill Evans, VP Quality 352-224-1634, if you have further questions.